Borges, Andreia; Pereira, Filipa; Redondo, Patrícia; … - In: Health Economics Review 11 (2021) 1, pp. 1-13
Background: Breast cancer (BC) is largely prevalent worldwide. HER2-positive BC account for roughly 20-25% of all BC cases and has an overall survival lower than other BC. Innovation on BC therapeutics is a constant, but novel therapies have higher costs. Therefore, cost-effectiveness research...
